Drugs / Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05561816 Comparator | Jul → Nov 2022 | pyoderma | Valenta Pharm JSC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05561816 ↗ |
| Route | Topical | “Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)” NCT05561816 ↗ |